Updates are available Correction dated 2024-01-10
Click to view Correction: https://doi.org/10.1038/s43018-024-00724-1
Updates are available Correction dated 2022-12-28
Click to view Correction: https://doi.org/10.1038/s43018-022-00507-6
-
Authors
Darragh, Laurel B. http://orcid.org/0000-0002-6445-7988
Knitz, Michael M. http://orcid.org/0000-0002-5786-9837
Hu, Junxiao
Clambey, Eric T.
Backus, Jennifer
Dumit, Andrew
Samedi, Von
Bubak, Andrew
Greene, Casey
Waxweiler, Timothy
Mehrotra, Sanjana
Bhatia, Shilpa
Gadwa, Jacob
Bickett, Thomas http://orcid.org/0000-0002-9905-9998
Piper, Miles
Fakhoury, Kareem
Liu, Arthur
Petit, Joshua
Bowles, Daniel
Thaker, Ashesh http://orcid.org/0000-0001-5238-0429
Atiyeh, Kimberly
Goddard, Julie
Hoyer, Robert
Van Bokhoven, Adrie http://orcid.org/0000-0002-6059-2429
Jordan, Kimberly
Jimeno, Antonio
D’Alessandro, Angelo
Raben, David
McDermott, Jessica D.
Karam, Sana D. http://orcid.org/0000-0003-1676-5967
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (F31 DE029997, 1R01DE028282-01, 1R01DE028529-01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1P50CA261605-01)
- License Information
-
More Information
Article History
Received: 26 February 2022
Accepted: 21 September 2022
First Online: 25 November 2022
Change Date: 28 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-022-00507-6
Competing interests
: S.D.K. is funded by Genentech for the ongoing phase II portion of this work, but there has been no overlap in the research. She is also funded by Roche and Ionis for work unrelated to the content of this manuscript. Though unrelated to the contents of this manuscript, the authors declare that A.D. is a founder of Omix Technologies Inc. A.D.A. is also a consultant for Altis Biosciences LLC, Rubius Inc. and Forma Inc. A.D.A. is a consultant for Hemanext Inc. A.J. has research support from NCI R01CA149456, R01DE024371, and P50CA261605; and stock/options ownership in Suvica and Champions Oncology. A.J.’s institution has contracts with Cantargia, DebioPharm, Genentech, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for trials where A.J. is the local P.I. All other authors declare no competing interests.
